After Hours
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
Zymeworks BC Inc is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. The current market capitalization of Zymeworks BC Inc is $1.19B. A total of 0.57 million shares were traded on the day, compared to an average of 644.61K shares.
In the most recent transaction, Galbraith Kenneth sold 18,198 shares of ZYME for 10.65 per share on Jan 05 ’24. After the transaction, the Chair & CEO now owns 29,468 company shares. In a previous transaction on Jan 08 ’24, Galbraith Kenneth sold 5,706 shares at 11.22 per share. ZYME shares that Chair & CEO owns now total 23,762.
Among the insiders who sold shares, Astle Christopher disposed of 4,563 shares on Jan 05 ’24 at a per-share price of $10.65. This resulted in the SVP & Chief Financial Officer holding 7,934 shares of ZYME after the transaction. In another insider transaction, Astle Christopher sold 1,431 shares at $11.22 per share on Jan 08 ’24. Company shares held by the SVP & Chief Financial Officer now total 6,503.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. In terms of 52-week highs and lows, ZYME has a high of $17.26 and a low of $6.83.
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. ZYME’s latest balance sheet shows that the firm has $252.61M in Cash & Short Term Investments as of fiscal 2021. There were $32.33M in debt and $71.85M in liabilities at the time. Its Book Value Per Share was $5.23, while its Total Shareholder’s Equity was $249.09M.
Analysts Opinion
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ZYME is Buy with a score of 4.25.
